Skip to main
BCYC

BCYC Stock Forecast & Price Target

BCYC Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 11%
Buy 44%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Bicycle Therapeutics PLC exhibits a promising outlook due to its innovative approach in developing the Bicycle Toxin Conjugates (BTCs), particularly evident in its lead product candidate, BT1718, which suggests potential advancements in efficacy and safety over existing therapies. The company's strategies to enhance treatment tolerability and deliver on-target results position it favorably against competitors, with investor interest spurred by the attractive opportunities in radiopharmaceuticals and expanded tumor targeting capabilities. Additionally, the positive comparisons with late-stage antibody-drug conjugates (ADCs) in oncology settings indicate a strong likelihood of robust commercial adoption and revenue growth potential, particularly as clinical validation continues to strengthen.

Bears say

Bicycle Therapeutics PLC faces a negative outlook primarily due to uncertainties surrounding its competitive positioning in the oncology market, especially following disappointing clinical trial results related to its product candidate, BT1718, which has exhibited a lower confirmed objective response rate compared to competitors. The company's decision to deprioritize the BT7480 program further reflects potential challenges in its clinical development processes, which may hinder advancement and value realization across its pipeline. Additionally, concerns about trial enrollment timelines, regulatory hurdles, and possible negative readouts could significantly delay commercialization efforts and decrease market potential, thereby impacting overall investor confidence and stock performance.

BCYC has been analyzed by 9 analysts, with a consensus rating of Buy. 11% of analysts recommend a Strong Buy, 44% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicycle Therapeutics Plc - ADR (BCYC) Forecast

Analysts have given BCYC a Buy based on their latest research and market trends.

According to 9 analysts, BCYC has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicycle Therapeutics Plc - ADR (BCYC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.